P17 CLONAL PLASMA-CELLS IN STEM CELL APHERESIS AS A PREDICTOR OF PROGRESSION IN NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS ELEGIBLE FOR AUTOLOGOUS STEM CELL TRANSPLANTATION

por Pilerci, S., Attucci, I., Pengue, L., Peruzzi, B., Caporale, R., Bencini, S., Messeri, M., Buzzichelli, A., Boncompagni, R., Nozzoli, C., Vannucchi, A.M., Antonioli, E.
Publicado 2023

P44 DETECTION OF SOLUBLE BCMA IN TEARS OF MM PATIENTS TREATED WITH BELANTAMAB MAFODOTIN

por Munawar, U., Theuersbacher, J., Haertle, L., Zhou, X., Han, S., Regensburger, A., Mersi, J., Bittrich, M., Seifert, F., Haider, M.S., Nerreter, S., Vogt, C., Teufel, E., Einsele, H., Rasche, L., Kampik, D., Kortüm, K.M.
Publicado 2023

B08 IDECABTAGENE VICLEUCEL VERSUS STANDARD REGIMENS IN PATIENTS WITH TRIPLE-CLASS–EXPOSED RELAPSED AND REFRACTORY MULTIPLE MYELOMA: KARMMA-3 A PHASE 3 RANDOMIZED CONTROLLED TRIAL...

por Rodríguez-Otero, P., Ailawadhi, S., Arnulf, B., Patel, K., Cavo, M., Nooka, A.K., Manier, S., Callander, N., Costa, L.J., Vij, R., Bahlis, N.J., Moreau, P., Solomon, S.R., Delforge, M., Berdeja, J., Truppel-Hartmann, A., Yang, Z., Favre-Kontula, L., Wu, F., Piasecki, J., Cook, M., Giralt, S.
Publicado 2023

B01 VENETOCLAX TARGETED THERAPY in AL AMYLOIDOSIS PATIENTS: A RETROSPECTIVE ANALYSIS FROM THE FRENCH AMYLOIDOSIS NETWORK

por Roussel, M., Pirotte, M., Gounot, R., Queru, K., Rizzo, O., Royer, B., Harel, S., Desport, E., Huart, A., Niault, M., Karlin, L., Decaux, O., Chalopin, T., Carpentier, B., Macro, M., Vignon, M., Chalayer, E., Stoppa, AM., Bridoux, F., Jaccard, A.
Publicado 2023

P58 LOW CD38 EXPRESSION BY PLASMA CELLS IN EXTRAMEDULLARY DISEASE IN MULTIPLE MYELOMA PATIENTS

por Notarfranchi, L., Accardi, F., Dalla Palma, B., Mancini, C., Martella, E., Bonomini, S., Storti, P., Toscani, D., Burroughs, J., Marchica, V., Sammarelli, G., Giuliani, N.
Publicado 2023

P11 COMBINED DIFFUSION WEIGHTED WHOLE BODY MRI (DW-MRI) AND MULTIPARAMETRIC FLOW CYTOMETRY (MFC) EVALUATION FOR MINIMAL RESIDUAL DISEASE DETECTION IN MULTIPLE MYELOMA PATIENTS: CON...

por Belotti, A., Ribolla, R., Crippa, C., Chiarini, M., Giustini, V., Ferrari, S., Peli, A., Cattaneo, C., Roccaro, A., Frittoli, B., Grazioli, L., Rossi, G., Tucci, A.
Publicado 2023

B09 CARTITUDE-2 COHORT B 18-MONTH FOLLOW-UP: CILTACABTAGENE AUTOLEUCEL (CILTA-CEL), A BCMA-DIRECTED CAR-T CELL THERAPY, IN PATIENTS WITH MULTIPLE MYELOMA (MM) AND EARLY RELAPSE AFT...

por Zweegman, S., Agha, M., Cohen, A.D., Cohen, Y.C., Anguille, S., Kerre, T., Roeloffzen, W., Madduri, D., Schecter, J.M., De Braganca, K.C., Jackson, C.C., Varsos, H., Mistry, P., Roccia, T., Xu, X., Li, K., Zudaire, E., Corsale, C., Akram, M., Geng, D., Pacaud, L., Sonneveld, P., van de Donk, N.
Publicado 2023

B04 IMPLEMENTING M-PROTEIN DIAGNOSTICS IN MULTIPLE MYELOMA PATIENTS USING ULTRA-SENSITIVE TARGETED MASS SPECTROMETRY DATA AND AN OFF-THE-SHELF CALIBRATOR

por Wijnands, C., Langerhorst, P., Noori, S., Gloerich, J., Bonifay, V., Touzeau, C., Corre, J., Perrot, A., Moreau, P., Caillon, H., Luider, T., van Gool, A., Dejoie, T., VanDuijn, M., Jacobs, J.
Publicado 2023

P43 CIRCULATING CLONAL PLASMA CELLS AT START OF SALVAGE REGIMEN PROVIDE POWERFUL PROGNOSTICATION BIOMARKER IN MULTIPLE MYELOMA PATIENTS AT FIRST RELAPSE

por Romano, A., Parrinello, N. L., Scandura, G., Marino, S., Triolo, A., Del Fabro, V., Di Raimondo, F., Conticello, C.
Publicado 2023

Orbital and Eyelid Characteristics, Strabismus, and Intracranial Pressure Control in Apert Children Treated by Endoscopic Strip Craniectomy versus Fronto-Orbital Advancement

por Dohlman, Jenny C., Prabhu, Sanjay P., Staffa, Steven J., Kanack, Melissa D., Mackinnon, Sarah, Warkad, Vivekanand U., Meara, John G., Proctor, Mark R., Dagi, Linda R.
Publicado 2023

P13 IXAZOMIB, DARATUMUMAB AND LOW-DOSE DEXAMETHASONE IN INTERMEDIATE-FIT PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA; RESULTS OF THE INDUCTION AND MAINTENANCE TREATMENT OF THE P...

por Groen, K., Stege, C., Nasserinejad, K., de Heer, K., van Kampen, R., Leys, R., Thielen, N., Westerman, M., Wu, K., Ludwig, I., Issa, D., Velders, G., Vekemans, M., van de Donk, N., Timmers, G., de Boer, F., Tick, L., van der Spek, E., de Waal, E., Sohne, M., Sonneveld, P., Nijhof, I., Klein, S., Levin, M., Ypma, P., Zweegman, S.
Publicado 2023

Deep Infantile Hemangioma in the Involuting Phase That Was Difficult to Diagnose before Surgery

por Sakai, Yuki, Tsuge, Itaru, Kataoka, Masako, Takeuchi, Yasuhide, Katayama, Yasuhiro, Yamanaka, Hiroki, Katsube, Motoki, Sowa, Yoshihiro, Sakamoto, Michiharu, Morimoto, Naoki
Publicado 2023

P06 MODELING DYNAMIC EVOLUTION OF MULTIPLE MYELOMA STUDYING CELL POPULATIONS METABOLISM AND COMPETITION UNDER MAXIMUM POWER CONSTRAINTS: A SYSTEMS-THINKING BASED APPROACH

por Romano, A., Conte, L., Giansanti, A., Kleidon, A., Gonella, F.
Publicado 2023

TREATMENT OF TRIPLE-CLASS REFRACTORY DISEASE: BEYOND IMMUNOTHERAPY

por Gavriatopoulou, M.
Publicado 2023

P52 RISK STRATIFICATION COMBINING SKY92 GENE EXPRESSION PROFILING AND TRADITIONAL FISH IN MULTIPLE MYELOMA: THE FIRST PROSPECTIVE EVIDENCE IN THE R2-ISS ERA

por Zhou, X., Hofmann, A., Vogt, C., Nerreter, S., Teufel, E., Stanojkovska, E., Truger, M., Engel, B., Xiao, X., Eisele, F., Weis, P., Barcic, A., Peter, J., Riedhammer, C., Steinhardt, M. J., Hornburger, H., Han, S., Haertle, L., Munawar, U., Mersi, J., Haferlach, C., Einsele, H., Kortüm, K. M., Rasche, L.
Publicado 2023

DEBATE UPFRONT vs DELAYED TRANSPLANT

por Gay, F.
Publicado 2023

P57 PRE-EXPOSURE PROPHYLAXIS FOR COVID-19 WITH TIXAGEVIMAB/CILGAVIMAB (EVUSHELD) IN PATIENTS WITH MULTIPLE MYELOMA

por Ntanasis-Stathopoulos, I., Gavriatopoulou, M., Eleutherakis-Papaiakovou, E., Malandrakis, P., Spiliopoulou, V., Syrigou, R.E., Theodorakakou, F., Fotiou, D., Migkou, M., Roussou, M., Kastritis, E., Dimopoulos, M.A., Terpos, E.
Publicado 2023

P05 ACETYL SALICYLIC ACID INDUCES POLARIZATION OF MACROPHAGES AND CYTOTOXICITY ON MYELOMA CELLS IN VITRO

por Gonulkirmaz, N., Beksac, M., Ozkan, T., Kar, I., Sunguroglu, A.
Publicado 2023

P14 OCULAR TOXICITY IN TRANSPLANT INELIGIBLE PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA TREATED WITH BELANTAMAB MAFODOTIN, LENALIDOMIDE AND DEXAMETHASONE IN A PHASE 1/2 TRIAL

por Ntanasis-Stathopoulos, I., Gavriatopoulou, M., Malandrakis, P., Fotiou, D., Kanellias, N., Migkou, M., Theodorakakou, F., Spiliopoulou, V., Syrigou, R., Eleutherakis-Papaiakovou, E., Gkolfinopoulos, S., Manousou, K., Kastritis, E., Dimopoulos, M.A., Terpos, E.
Publicado 2023

P29 PHASE 1/2 RESULTS OF TALQUETAMAB, A G PROTEIN-COUPLED RECEPTOR FAMILY C GROUP 5 MEMBER D X CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM)...

por Minnema, M.C., Chari, A., Touzeau, C., Schinke, C., Berdeja, J., Oriol, A., van, de Donk N., Otero, P.R., Askari, E., Mateos, M.V., Costa, L.J., Caers, J., Rasche, L., Krishnan, A., Vishwamitra, D., Ma, X., Qin, X., Gries, K.S., Campagna, M., Masterson, T., Hilder, B., Tolbert, J., Renaud, T., Goldberg, J.D., Heuck, C., Miguel, J.S., Moreau, P.
Publicado 2023